Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

Part of paid clinical trials in Great Neck, New York.

Sponsor: Northwell Health
Study ID: NCT07061847
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Migraine

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

Lidocaine (drug) — DRUG
The study intervention involves the use of 1% cardiac preservative-free lidocaine. Lidocaine is a local anesthetic commonly used in medical procedures to numb a specific area of the body. In this case, the lidocaine is formulated at a concentration of 1% and will be diluted to 50 mL with normal saline. This treatment is an intra-arterial bilateral lidocaine infusion into the middle meningeal artery (i.e. this is a lidocaine infusion into the brain blood vessels to turn off the pain receptors responsible for causing chronic headaches). Lidocaine is an FDA approved anesthetic (i.e. pain killer) used in common medical practice. Lidocaine, however, has not yet been approved by the FDA for this particular use. For this reason, the use of lidocaine in this study is considered investigational.
Lidocaine Procedure — PROCEDURE
All patient who meet eligibility criteria at their baseline visit will be scheduled for the Liocaine procedure.

Study Details

The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, frequency, and duration.